Showing results (151-160 of 5,263) with videos related to

Sort By:
Pageof 527
European Journal of Haematology|May 9, 2021
Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myelomaGudbjorg Jonsdottir, Magnus Björkholm, Ingemar Turesson, et al.
European Journal of Haematology|February 6, 1998
The management of crisis in sickle cell diseaseI Okpala
European Journal of Haematology|February 6, 1998
African iron overload and hepatocellular carcinoma (HA-7-0-080)V M Moyo, R Makunike, I T Gangaidzo, et al.
European Journal of Haematology|April 21, 1998
Circadian-based effects of AcSDKP, with or without rhG-CSF on hematologic toxicity of chemotherapy in miceX M Li, C Soulard, E Filipski, et al.
European Journal of Haematology|May 23, 2020
Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group"Maria Gabriella Mazzucconi, Ermina Baldacci, Roberto Latagliata, et al.
European Journal of Haematology|September 18, 2021
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study GroupHenrik Gregersen, Valdas Peceliunas, Kari Remes, et al.
European Journal of Haematology|September 8, 2021
Impact of therapeutic management and geriatric evaluation on patient of eighty years and older with diffuse large B-cell lymphoma on survival: A systematic reviewMarguerite Briand, Stephane Gerard, Martin Gauthier, et al.
European Journal of Haematology|July 25, 2015
Neurological symptoms in essential thrombocythemia: impact of JAK2V617F mutation and response to therapyAndrea Aroldi, Caterina Cecchetti, Arianna Colombo, et al.
European Journal of Haematology|May 29, 2015
Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overloadMohsen S Elalfy, Maha M Saber, Amira Abdel Moneam Adly, et al.
European Journal of Haematology|May 29, 2015
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemiaMaria Teresa Voso, Pasquale Niscola, Alfonso Piciocchi, et al.
Pageof 527